Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Gastroesophageal Cancer
Is there a role for a PDL-1 inhibitor in patients with chemo-refractory metastatic esophageal adenocarcinoma with PDL negative, MSI stable disease?
In a patient with a good performance status, would you consider this?
Related Questions
When do you consider performing a diagnostic laparoscopy before neoadjuvant chemotherapy in pancreatic adenocarcinoma patients?
How do you interpret discrepancies between MMR testing and MSI testing?
What would you do for a patient with oligometastatic colon NEC (GEP-NEC) who only achieved stable disease after 4 cycles of carboplatin/etoposide?
Would you ever use a PET dotatate CT to monitor response of a GEP-NEN that is SSTR positive?
When do you feel comfortable adding bevacizumab to a BRAF-WT, KRAS-mutated colon cancer patient with previously hemorrhagic brain mets that responded to radiation?
Would you offer adjuvant chemotherapy after SBRT for biopsy proven sub centimeter metastatic pulmonary nodule from rectal cancer?
Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?
How long do you treat with immunotherapy patients with MSI-high T4B initially unresectable colon adenocarcinoma?
Do you offer a curative surgery (Whipple procedure) to patients with duodenal adenocarcinoma, with 2-5 liver metastases, and with near CR after 3-6 months of FOLFOX chemotherapy?
How do you manage patients with suspected cholangiocarcinoma that presents with biliary obstruction but has repeated negative brushings/biopsies?